A randomized double blind studyh of Ruxolitinib or placebo in combination with Regorafenib in subjects with relapsed or refractory metastatic colorectal cancer.
Administered By
Awarded By
Contributors
- Hurwitz, Herbert Ira Principal Investigator
Start/End
- October 1, 2014 - September 30, 2019